文献速递血栓与止血

超长效因子VIII:迈向无血友病心智的重要一步

Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind.
PubMed 文献 · J Thromb Haemost · 2024-04-27

本文评述了血友病A治疗领域的重大进展——超长效修饰因子VIII(efanesoctocog alfa)的开发。该分子借助免疫球蛋白Fc片段融合、通过D'-D3片段使FVIII与内源性血管性血友病因子解离,以及添加亲水性多肽带来的药代动力学延长,使FVIII矫正水平在正常范围内维持数天,从而使更多患者摆脱血友病A的躯体与心理束缚。

要点

  • efanesoctocog alfa通过Fc融合、D'-D3片段解离vWF及亲水性多肽延长半衰期。
  • 该分子使FVIII矫正水平在正常范围内维持数天。
  • 每周静脉输注的负担仍存在,但止血矫正的幅度与持续时间目前无其他疗法可比。

核心结论

  • 超长效修饰因子VIII的开发是血友病A治疗的一项显著进步,开启了血友病A治疗的新纪元。

研究设计与样本

  • 本文为评述性文章,未报告系统检索范围或样本量。

主要发现

  • efanesoctocog alfa借助免疫球蛋白Fc片段融合经验、通过D'-D3片段使FVIII与内源性血管性血友病因子解离,并受益于添加亲水性多肽提供的药代动力学延长。
  • 该分子提供的FVIII矫正水平在正常范围内维持数天。
  • 每周静脉输注的负担持续存在,但被止血矫正的幅度与持续时间所补偿,目前其他可选疗法无法与之匹敌。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A remarkable step forward in the treatment of hemophilia A has recently been achieved with the development of an Ultra-Long modified factor (F)VIII. Leveraging expertise gained with fusion to immunoglobulin Fc fragments, disconnecting FVIII from endogenous von Willebrand factor (via a D'-D3 fragment), and benefiting from the pharmacokinetic prolongation provided by the addition of hydrophilic polypeptides, efanesoctocog alfa opens a new era in the treatment of hemophilia A. The term Ultra-Long FVIII has been proposed to designate it and differentiate it from extended half-life FVIII. The level of FVIII correction within the normal range for several days provided by this molecule should allow an increasing number of patients to free themselves from the physical and psychological constraints of hemophilia A. Certainly, the burden of weekly intravenous infusions persists but is compensated by a correction of hemostasis whose amplitude and duration remain unmatched by other therapeutic options currently available.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hermans C, Pierce GF. Ultra-Long factor VIII: a major step forward toward a hemophilia-free mind. J Thromb Haemost. 2024. PMID: 38679336. doi:10.1016/j.jtha.2024.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。